ODDO BHF initiates coverage of Carvolix
with an Outperform rating

Aix-en-Provence, July 29, 2026 – Carvolix (formerly Affluent Medical) (ISIN: FR0013333077 – Ticker: CVX), a French commercial and clinical-stage medical technology company specializing in the international development, industrialization and commercialization of breakthrough AI-driven mini-robots and biomimetic implants, today announces the initiation of coverage of its shares by ODDO BHF.

In its research report entitled “A multi-specialty interventional platform”, published on 28 July 2026, ODDO BHF initiated coverage of Carvolix with an Outperform rating and a price target of €10.50, representing an upside potential of 89% compared with the closing share price on 28 July 2026.

This initiation further broadens the Company’s equity research coverage and expands the analyst consensus, alongside Allinvest Securities, Kepler Cheuvreux, Portzamparc Groupe BNP Paribas and TP ICAP.

The recommendations, estimates, and price targets mentioned in this press release are those of ODDO BHF and reflect solely the analysis of that firm.

This press release does not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, securities in France, Europe, the United States or any other jurisdiction.

Carvolix is a French medical technologies company, commercial and clinical stage, founded by Truffle Capital (also founder of the top European biotech company), that aims to become a global leader in the treatment of structural heart diseases and brain strokes, the world's leading causes of mortality and disability. According to the Truffle 10 MedTech Index, Carvolix ranks number one in Europe and number six worldwide. Carvolix develops novel AI and imaging driven mini robots that make complex procedures doable by interventional cardiologists, as well as biomimetic heart valves.

For more information: www.carvolix.eu

Contacts